View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 2, 2018

Takeda closes TiGenix acquisition for about $608m

Takeda Pharmaceutical has completed its purchase of all outstanding ordinary shares of Belgium-based TiGenix for approximately $608.84m (€520m), representing €1.78 per share.

Takeda Pharmaceutical has completed its purchase of all outstanding ordinary shares of Belgium-based TiGenix for approximately $608.84m (€520m), representing €1.78 per share.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

Takeda revealed its plans to acquire the biopharmaceutical firm in January this year, under an offer and support agreement for a voluntary public takeover bid.

The closing of the transaction follows the expiration of the squeeze-out period, which started on 6 July and expired on 26 July this year.

With the completion of the deal, Takeda gains 100% securities with voting rights or providing access to the rights of TiGenix that are not already held by the company or its affiliates.

As a result, TiGenix becomes a wholly-owned subsidiary of Takeda.

Takeda expects the acquisition to bolster its late-stage gastroenterology pipeline along with a footprint in the specialist care market of the US.

The deal additionally expands an ongoing alliance between Takeda and TiGenix focused on the development of new therapies for patients suffering from gastrointestinal conditions.

“We can be most effective in serving this population by working in collaboration with partners whose unique skill sets allow us to more efficiently explore innovative approaches.”

In July 2016, the companies signed an exclusive licence, development and commercialisation agreement for one of TiGenix ’s investigational compounds, Cx601, in ex-US markets.

Cx601 is a suspension of allogeneic expanded adipose-derived stem cells (eASC). It is being developed to treat complex perianal fistulas caused due to non-active/mildly active luminal Crohn’s disease.

Takeda chief medical and scientific officer Andrew Plump said: “Limited treatment options exist today and I believe we can be most effective in serving this population by working in collaboration with partners whose unique skill sets allow us to more efficiently explore innovative approaches, including stem cell therapies.”

Takeda primarily works towards addressing gastroenterology disorders with high unmet need such as inflammatory bowel disease, acid-related diseases and motility disorders.

The company also aims to provide new treatment options, including microbiome therapies, for celiac and advanced liver diseases.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

Topics in this article: ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology